Alphamab, Sanofi collaborate for breast cancer research
Singapore, June 17 -- China based Alphamab Oncology, a clinical stage biopharmaceutical company focusing on innovative biologics medicine for oncology, and Sanofi, a global biopharmaceutical leader, announced have that Jiangsu Alphamab Biopharmaceuticals Co., Ltd., a wholly-owned subsidiary of Alphamab Oncology, signed an agreement with Sanofi (China) Investment Co., Ltd to establish strategic collaboration to advance clinical studies to investigate KN026 in combination with Taxotere(R) (Docetaxel) in HER2+ breast cancer, and Sanofi is granted an exclusivity period to negotiate the in-licensing of KN026 subject to the achievement of certain clinical milestones.
KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two n...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.